Encouraging results for HER3-Targeting therapy in Leptomeningeal Metastatic Disease
Table of Contents
A new study presented at the 2025 ASCO Annual Meeting highlights the potential of patritumab deruxtecan in treating leptomeningeal metastatic disease.
CHICAGO – New research indicates that the HER3-targeting antibody-drug conjugate, patritumab deruxtecan, is showing promise in patients with leptomeningeal metastatic disease originating from various solid tumors. The findings, presented at the 2025 ASCO Annual Meeting, come from cohort 3 of the phase 2 TUXEDO-3 trial.
Patritumab Deruxtecan Demonstrates Encouraging Survival Rates
The TUXEDO-3 trial focused on patients with leptomeningeal metastatic disease, a condition were cancer cells spread to the membranes surrounding the brain and spinal cord. This complication is ofen associated with poor prognosis and limited treatment options. The study explored the efficacy of patritumab deruxtecan in this challenging patient population.
“Patients…showed encouraging 3-month overall survival rates.”
Preliminary results from cohort 3 suggest that treatment with patritumab deruxtecan lead to encouraging 3-month overall survival rates. These findings offer a potential new avenue for managing leptomeningeal metastatic disease, warranting further investigation and larger-scale clinical trials.
Understanding Leptomeningeal Metastatic Disease
Frequently Asked Questions
- What is patritumab deruxtecan?
- Patritumab deruxtecan is an antibody-drug conjugate that targets the HER3 protein, which is frequently enough overexpressed in cancer cells. It delivers a cytotoxic drug directly to cancer cells, aiming to minimize damage to healthy tissues.
- What is the TUXEDO-3 trial?
- The TUXEDO-3 trial is a phase 2 clinical trial evaluating the efficacy and safety of patritumab deruxtecan in patients with leptomeningeal metastatic disease from solid tumors.
- what are the symptoms of leptomeningeal metastatic disease?
- Symptoms can vary but may include headaches, seizures, changes in mental status, weakness, and sensory abnormalities.
Sources
